Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 1/20 | 0.79 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.51 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphine SCHEMBL29079498 | 0.98 | HRH1 (0.77) | HRH1SLC6A4RIPK1SLC6A2TAAR1 | |
| SCHEMBL1569927 | 0.89 | HRH1 (1.00) | HRH1SLC6A4RIPK1SLC6A2TAAR1 | |
| Hydrochloric Acid SCHEMBL6963688 | 0.87 | HRH1 (0.96) | HRH1SLC6A4RIPK1SLC6A2TAAR1 | |
| SCHEMBL5105918 | 0.85 | HRH1 (0.68) | HRH1SLC6A4RIPK1SLC6A2TAAR1 | |
| SCHEMBL8423083 | 0.82 | HRH1 (0.55) | HRH1SLC6A4SLC6A2TAAR1HTR2A | |
| SCHEMBL6503487 | 0.81 | HRH1 (0.62) | HRH1SLC6A4RIPK1SLC6A2CYP19A1 | |
| SCHEMBL1070099 | 0.81 | HRH1 (0.62) | HRH1SLC6A4RIPK1SLC6A2CYP19A1 | |
| SCHEMBL7646958 | 0.81 | HRH1 (0.62) | HRH1SLC6A4RIPK1SLC6A2CYP19A1 | |
| SCHEMBL29580562 | 0.81 | HRH1 (0.62) | HRH1SLC6A4RIPK1SLC6A2LTA4H | |
| SCHEMBL5389689 | 0.81 | HRH1 (0.62) | HRH1SLC6A4RIPK1SLC6A2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9770442-B2 | Self-assembling amphiphilic polymers as anti-cancer agents | ALLEXCEL INC. (US) | 2017-09-26 | — | — | US | disclosed |
| EP-2167103-B1 | SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTICANCER AGENTS | ALLEXCEL INC (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-2120974-B1 | SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTIVIRAL AGENTS | ALLEXCEL INC (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-1979407-B1 | SOLUBILIZATION AND TARGETED DELIVERY OF DRUGS WITH SELF-ASSEMBLING AMPHIPHILIC POLYMERS | ALLEXCEL INC (US) | 2014-08-06 | — | — | EP | disclosed |
| US-8173764-B2 | Solubilization and targeted delivery of drugs with self-assembling amphiphilic polymers | ALLEXCEL INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20100260743-A1 | Solubilization and Targeted Delivery of Drugs With Self-Assembling Amphiphilic Polymers | ALLEXCEL, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100239659-A1 | SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTI-CANCER AGENTS | ALLEXCEL., INC. (US) | 2010-09-23 | — | — | US | disclosed |
| EP-2167103-A1 | SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTICANCER AGENTS | Allexcel, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20100008938-A1 | SELF ASSEMBLING AMPHIPHILIC POLYMERS AS ANTIVIRAL AGENTS | ALLEXCEL, INC. | 2010-01-14 | — | — | US | disclosed |
| EP-2120974-A1 | SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTIVIRAL AGENTS | Allexcel, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| EP-1458368-B1 | USE OF NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF COGNITIVE FAILURE | LILLY CO ELI (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2007084126-A1 | SOLUBILIZATION AND TARGETED DELIVERY OF DRUGS WITH SELF-ASSEMBLING AMPHIPHILIC POLYMERS | ALLEXCEL, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| CN-1713900-A | Use of norepinephrine reuptake inhibitors for the treatment of cognitive disorders | LILLY CO ELI (US) | 2005-12-28 | — | — | CN | disclosed |
| US-20050009925-A1 | Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure | BYMASTER FRANKLIN PORTER (US) | 2005-01-13 | — | — | US | disclosed |
| EP-1458368-A1 | USE OF NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF COGNITIVE FAILURE | ELI LILLY AND COMPANY (US) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003049724-A1 | USE OF NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF COGNITIVE FAILURE | ELI LILLY AND COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| EP-0545425-B1 | 2-(3-Phenylpropyl)hydrazines, intermediates in and a process for the preparation thereof, and their use as medicaments | HOECHST ROUSSEL PHARMA (US) | 1996-03-20 | — | — | EP | disclosed |
| US-5268468-A | Or optical isomers thereof | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-12-07 | — | — | US | disclosed |
| US-5229417-A | Obsessive compulsive disorders | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-07-20 | — | — | US | disclosed |
| EP-0545425-A1 | 2-(3-Phenylpropyl)hydrazines, intermediates in and a process for the preparation thereof, and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009925-A1 | Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure | SLC6A2, PNMT, SLC6A3 | HRH1 2171/4885SLC6A4 4/4885RIPK1 4409/4885 |
| US-20100008938-A1 | SELF ASSEMBLING AMPHIPHILIC POLYMERS AS ANTIVIRAL AGENTS | PICALM, CLTA, HAVCR2 | HRH1 2520/4885SLC6A4 3464/4885RIPK1 1611/4885 |
| US-20100239659-A1 | SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTI-CANCER AGENTS | CD44, EPCAM, EGFR | HRH1 1405/4885SLC6A4 3266/4885RIPK1 2726/4885 |
| US-20100260743-A1 | Solubilization and Targeted Delivery of Drugs With Self-Assembling Amphiphilic Polymers | CD44, ABCG2, ABCC1 | HRH1 1533/4885SLC6A4 826/4885RIPK1 3190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.